Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

DNA repair of myeloma plasma cells correlates with clinical outcome: the effect of the nonhomologous end-joining inhibitor SCR7.

Gkotzamanidou M, Terpos E, Bamia C, Munshi NC, Dimopoulos MA, Souliotis VL.

Blood. 2016 Sep 1;128(9):1214-25. doi: 10.1182/blood-2016-01-691618. Epub 2016 Jul 21.

2.

Neutrophil Gelatinase--Associated Lipocalin and Cystatin C Are Sensitive Markers of Renal Injury in Patients With Multiple Myeloma.

Papassotiriou GP, Kastritis E, Gkotzamanidou M, Christoulas D, Eleutherakis-Papaiakovou E, Migkou M, Gavriatopoulou M, Roussou M, Margeli A, Papassotiriou I, Dimopoulos MA, Terpos E.

Clin Lymphoma Myeloma Leuk. 2016 Jan;16(1):29-35. doi: 10.1016/j.clml.2015.10.003. Epub 2015 Nov 3.

PMID:
26632077
3.

Chromatin structure, transcriptional activity and DNA repair efficiency affect the outcome of chemotherapy in multiple myeloma.

Gkotzamanidou M, Sfikakis PP, Kyrtopoulos SA, Bamia C, Dimopoulos MA, Souliotis VL.

Br J Cancer. 2014 Sep 23;111(7):1293-304. doi: 10.1038/bjc.2014.410. Epub 2014 Jul 22.

4.

Hematologic response and stabilization of renal function in a patient with light chain deposition disease after lenalidomide treatment: a novel therapeutic approach?

Gkotzamanidou M, Terpos E, Kastritis E, Dimopoulos MA.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e179-81. doi: 10.1016/j.clml.2014.06.002. Epub 2014 Jun 10. No abstract available.

PMID:
25022598
5.

Angiogenic cytokines profile in smoldering multiple myeloma: no difference compared to MGUS but altered compared to symptomatic myeloma.

Gkotzamanidou M, Christoulas D, Souliotis VL, Papatheodorou A, Dimopoulos MA, Terpos E.

Med Sci Monit. 2013 Dec 20;19:1188-94. doi: 10.12659/MSM.889752.

6.

Progressive changes in chromatin structure and DNA damage response signals in bone marrow and peripheral blood during myelomagenesis.

Gkotzamanidou M, Terpos E, Bamia C, Kyrtopoulos SA, Sfikakis PP, Dimopoulos MA, Souliotis VL.

Leukemia. 2014 May;28(5):1113-21. doi: 10.1038/leu.2013.284. Epub 2013 Oct 3.

PMID:
24089038
7.

Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.

Gkotzamanidou M, Papadimitriou CA.

Crit Rev Oncol Hematol. 2014 Feb;89(2):248-61. doi: 10.1016/j.critrevonc.2013.08.016. Epub 2013 Sep 8. Review.

PMID:
24075060
8.

VTD consolidation, without bisphosphonates, reduces bone resorption and is associated with a very low incidence of skeletal-related events in myeloma patients post ASCT.

Terpos E, Christoulas D, Kastritis E, Roussou M, Migkou M, Eleutherakis-Papaiakovou E, Gavriatopoulou M, Gkotzamanidou M, Kanellias N, Manios E, Papadimitriou C, Dimopoulos MA.

Leukemia. 2014 Apr;28(4):928-34. doi: 10.1038/leu.2013.267. Epub 2013 Sep 18.

PMID:
24045498
9.

The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group.

Terpos E, Christoulas D, Kastritis E, Katodritou E, Papatheodorou A, Pouli A, Kyrtsonis MC, Michalis E, Papanikolaou X, Gkotzamanidou M, Koulieris E, Gavriatopoulou M, Zervas K, Dimopoulos MA; Greek Myeloma Study Group.

Am J Hematol. 2014 Jan;89(1):34-40.

10.

Transcription factor-pathway coexpression analysis reveals cooperation between SP1 and ESR1 on dysregulating cell cycle arrest in non-hyperdiploid multiple myeloma.

Wang X, Yan Z, Fulciniti M, Li Y, Gkotzamanidou M, Amin SB, Shah PK, Zhang Y, Munshi NC, Li C.

Leukemia. 2014 Apr;28(4):894-903. doi: 10.1038/leu.2013.233. Epub 2013 Aug 8.

11.

Extensive bone marrow infiltration and abnormal free light chain ratio identifies patients with asymptomatic myeloma at high risk for progression to symptomatic disease.

Kastritis E, Terpos E, Moulopoulos L, Spyropoulou-Vlachou M, Kanellias N, Eleftherakis-Papaiakovou E, Gkotzamanidou M, Migkou M, Gavriatopoulou M, Roussou M, Tasidou A, Dimopoulos MA.

Leukemia. 2013 Apr;27(4):947-53. doi: 10.1038/leu.2012.309. Epub 2012 Nov 6.

PMID:
23183429
12.

The role of novel agents on the reversibility of renal impairment in newly diagnosed symptomatic patients with multiple myeloma.

Dimopoulos MA, Roussou M, Gkotzamanidou M, Nikitas N, Psimenou E, Mparmparoussi D, Matsouka C, Spyropoulou-Vlachou M, Terpos E, Kastritis E.

Leukemia. 2013 Feb;27(2):423-9. doi: 10.1038/leu.2012.182. Epub 2012 Jul 5.

PMID:
22763386
13.

Sclerostin: a possible target for the management of cancer-induced bone disease.

Gkotzamanidou M, Dimopoulos MA, Kastritis E, Christoulas D, Moulopoulos LA, Terpos E.

Expert Opin Ther Targets. 2012 Aug;16(8):761-9. doi: 10.1517/14728222.2012.697154. Epub 2012 Jul 5. Review.

PMID:
22762409
14.

Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.

Moulopoulos LA, Dimopoulos MA, Kastritis E, Christoulas D, Gkotzamanidou M, Roussou M, Koureas A, Migkou M, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Gika D, Koutoulidis V, Terpos E.

Am J Hematol. 2012 Sep;87(9):861-4. doi: 10.1002/ajh.23258. Epub 2012 May 28.

15.

High circulating sclerostin is present in patients with thalassemia-associated osteoporosis and correlates with bone mineral density.

Voskaridou E, Christoulas D, Plata E, Bratengeier C, Anastasilakis AD, Komninaka V, Kaliontzi D, Gkotzamanidou M, Polyzos SA, Dimopoulou M, Terpos E.

Horm Metab Res. 2012 Nov;44(12):909-13. doi: 10.1055/s-0032-1312618. Epub 2012 May 11.

PMID:
22581647
16.

Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents.

Tasidou A, Roussou M, Terpos E, Kastritis E, Gkotzamanidou M, Gavriatopoulou M, Migkou M, Eleutherakis-Papaiakovou E, Nikitas N, Anagnostou D, Dimopoulos MA.

Am J Hematol. 2012 Jul;87(7):734-6. doi: 10.1002/ajh.23223. Epub 2012 May 6.

17.

Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy.

Terpos E, Kastritis E, Christoulas D, Gkotzamanidou M, Eleutherakis-Papaiakovou E, Kanellias N, Papatheodorou A, Dimopoulos MA.

Ann Oncol. 2012 Oct;23(10):2681-6. Epub 2012 Apr 6.

PMID:
22492699
18.

Development and validation of a PCR-based assay for the selection of patients more likely to benefit from therapeutic treatment with alkylating drugs.

Stefanou DT, Episkopou H, Kyrtopoulos SA, Bamias A, Gkotzamanidou M, Bamia C, Liakou C, Bekyrou M, Sfikakis PP, Dimopoulos MA, Souliotis VL.

Br J Clin Pharmacol. 2012 Nov;74(5):842-53. doi: 10.1111/j.1365-2125.2012.04274.x.

19.

Renal impairment is not an independent adverse prognostic factor in patients with multiple myeloma treated upfront with novel agent-based regimens.

Eleftherakis-Papapiakovou E, Kastritis E, Roussou M, Gkotzamanidou M, Grapsa I, Psimenou E, Nikitas N, Terpos E, Dimopoulos MA.

Leuk Lymphoma. 2011 Dec;52(12):2299-303. doi: 10.3109/10428194.2011.597906.

PMID:
22141916
20.

Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.

Terpos E, Christoulas D, Katodritou E, Bratengeier C, Gkotzamanidou M, Michalis E, Delimpasi S, Pouli A, Meletis J, Kastritis E, Zervas K, Dimopoulos MA.

Int J Cancer. 2012 Sep 15;131(6):1466-71. doi: 10.1002/ijc.27342. Epub 2011 Dec 21.

21.

Increased serum lactate dehydrongenase should be included among the variables that define very-high-risk multiple myeloma.

Gkotzamanidou M, Kastritis E, Gavriatopoulou MR, Nikitas N, Gika D, Mparmparousi D, Matsouka C, Terpos E, Dimopoulos MA.

Clin Lymphoma Myeloma Leuk. 2011 Oct;11(5):409-13. doi: 10.1016/j.clml.2011.07.001. Epub 2011 Sep 8.

PMID:
21903504
22.

Response to bortezomib of a patient with scleromyxedema refractory to other therapies.

Migkou M, Gkotzamanidou M, Terpos E, Dimopoulos MA, Kastritis E.

Leuk Res. 2011 Nov;35(11):e209-11. doi: 10.1016/j.leukres.2011.07.021. Epub 2011 Aug 9. No abstract available.

PMID:
21831425
23.

Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.

Zagouri F, Roussou M, Kastritis E, Koureas A, Tsokou E, Migkou M, Gavriatopoulou M, Nikitas N, Gkotzamanidou M, Terpos E, Dimopoulos MA.

Am J Hematol. 2011 Oct;86(10):882-4. doi: 10.1002/ajh.22135. Epub 2011 Aug 4. No abstract available.

24.

Short progression-free survival predicts for poor overall survival in older patients with multiple myeloma treated upfront with novel agent-based therapy.

Migkou M, Kastritis E, Roussou M, Gkotzamanidou M, Gavriatopoulou M, Nikitas N, Mparmparoussi D, Matsouka C, Gika D, Terpos E, Dimopoulos MA.

Eur J Haematol. 2011 Oct;87(4):323-9. doi: 10.1111/j.1600-0609.2011.01659.x. Epub 2011 Aug 26.

PMID:
21631590
25.

Circulating angiopoietin-1 to angiopoietin-2 ratio is an independent prognostic factor for survival in newly diagnosed patients with multiple myeloma who received therapy with novel antimyeloma agents.

Terpos E, Anargyrou K, Katodritou E, Kastritis E, Papatheodorou A, Christoulas D, Pouli A, Michalis E, Delimpasi S, Gkotzamanidou M, Nikitas N, Koumoustiotis V, Margaritis D, Tsionos K, Stefanoudaki E, Meletis J, Zervas K, Dimopoulos MA; Greek Myeloma Study Group, Greece.

Int J Cancer. 2012 Feb 1;130(3):735-42. doi: 10.1002/ijc.26062. Epub 2011 May 30.

26.

Expression of CCL3 by neoplastic cells in patients with Waldenström's macroglobulinemia: an immunohistochemical study in bone marrow biopsies of 67 patients.

Terpos E, Tasidou A, Eleftherakis-Papaiakovou E, Christoulas D, Gavriatopoulou M, Gkotzamanidou M, Roussou M, Kastritis E, Papadaki T, Dimopoulos MA.

Clin Lymphoma Myeloma Leuk. 2011 Feb;11(1):115-7. doi: 10.3816/CLML.2011.n.024.

PMID:
21454208
27.

Treatment of patients with relapsed/refractory multiple myeloma with lenalidomide and dexamethasone with or without bortezomib: prospective evaluation of the impact of cytogenetic abnormalities and of previous therapies.

Dimopoulos MA, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Gkotzamanidou M, Iakovaki M, Matsouka C, Mparmparoussi D, Roussou M, Efstathiou E, Terpos E.

Leukemia. 2010 Oct;24(10):1769-78. doi: 10.1038/leu.2010.175. Epub 2010 Aug 26.

PMID:
20739955
28.

Diffuse MRI marrow pattern correlates with increased angiogenesis, advanced disease features and poor prognosis in newly diagnosed myeloma treated with novel agents.

Moulopoulos LA, Dimopoulos MA, Christoulas D, Kastritis E, Anagnostou D, Koureas A, Roussou M, Gavriatopoulou M, Migkou M, Iakovaki M, Gkotzamanidou M, Tasidou A, Terpos E.

Leukemia. 2010 Jun;24(6):1206-12. doi: 10.1038/leu.2010.70. Epub 2010 Apr 29. No abstract available.

PMID:
20428203
29.

Dickkopf-1: a suitable target for the management of myeloma bone disease.

Gavriatopoulou M, Dimopoulos MA, Christoulas D, Migkou M, Iakovaki M, Gkotzamanidou M, Terpos E.

Expert Opin Ther Targets. 2009 Jul;13(7):839-48. doi: 10.1517/14728220903025770. Review.

PMID:
19530987

Supplemental Content

Loading ...
Support Center